Declozindol

Declozindol is mazindol with the chlorine stripped off, and that small change re-weights its pharmacology. Where mazindol hits dopamine, noradrenaline, and serotonin transporters, declozindol is strongly noradrenaline-biased (NET around 2.8 nM versus DAT 730 nM and SERT 2140 nM), so it wakes you up with less of the dopaminergic and serotonergic baggage that raises abuse and side-effect risk. On top of that, like the mazindol narcolepsy program, it keeps partial agonism at the orexin-2 receptor; orexin is the exact signal narcoleptics lack, so the pitch is a small-molecule orexin-forward wake stabilizer rather than a blunt stimulant.

Research compound with no human safety data. Noradrenergic wake drugs can raise heart rate and blood pressure and cause jitteriness or insomnia, and the orexin angle is still experimental. As a mazindol relative, appetite suppression is plausible. Not an approved medication; laboratory use only.